

Claims

1. Pharmaceutical product with active ingredients affecting the central nervous system, with addition of a substance active in the nasal mucous membrane for endonasal administration, characterized in that a combined composition of free radical products with biologically active substances are administered for potentiating the efficacy, wherein the increased efficacy occurs in combination with oxygen anion radicals (SAR) and/or nitrogen oxide active products.
2. Pharmaceutical product according to claim 1, characterized in that the potentiation is attained by drug-like substances and different types of metabolites, and such substances of a chemical nature.
3. Pharmaceutical product according to claim 1, characterized in that the potentiation is attained in conjunction with different types of free radicals (SAR, NO-radicals) and/or corresponding radical formers.
4. Pharmaceutical product according to claim 1, characterized in that the substances active in the nasal mucous membrane are perhydroxyl radicals, hydrogen peroxide, hydroperoxide radicals or their hydrate clusters.
5. Pharmaceutical product according to claim 1, characterized in that the substances active in the nasal mucous membrane are forms of nitrogen monoxide (NO) and their precursors or reaction products.
6. Pharmaceutical product according to claim 1, characterized in that the substances active in the nasal mucous membrane are biochemical, physiological vaso-dilators, preferably arginin, bradykinin, urea or eicosatric acid-derivates.
7. Pharmaceutical product according to claims 1 to 6, characterized by a mixture comprising substances active in the nasal mucous membrane in a concentration of 10^{-12} mole/l to 10^{-1} mole/l.

8. Pharmaceutical product according to claims 1 to 6, characterized by a mixture comprising substances active in the nasal mucous membrane in a concentration of 10^{-5} .
9. Pharmaceutical product according to claims 1 to 8, characterized in that conventional drug substances are included in a dose of 0.001 mg to 100 mg per dosage unit.
10. Pharmaceutical product according to claims 1 to 9, characterized in that the metabolite is included in a dose of 0.0001 mg to 100 mg per dosage unit.
11. Pharmaceutical product according to claims 1 to 10, characterized in that the drug substances are promedol, metamizol, phenobarbital, methadone, tramadol, ASS or sildenafil.
12. Pharmaceutical product according to claim 12, characterized in that the metabolite is tryptophan, gamma-amino butyric acid, oxytocin, dermorphin, cyclic GMP, glucose, dopamine, or L-dopa.
13. Pharmaceutical product according to claims 1 to 13, characterized in that one or more of its active components are present in the composition as liposomes and/or nanosomes.
14. Pharmaceutical product according to claims 1 to 14, characterized in that one or more of its active components are present in the composition in a form different from the solution.
15. Pharmaceutical product according to claims 1 to 15, characterized in that pharmaceutically acceptable, auxiliary substances are present in the composition.
16. Pharmaceutical product according to claims 1 to 16, characterized in that the auxiliary substances are stabilizers, antioxidants, pH regulators, osmo-regulators or antimicrobial substances, which are present in the product in combination with a pharmaceutical substance adequate for its administration.
17. Pharmaceutical product according to claims 1 to 17, characterized in that the product is a

spray that can be endonasally administered.